CL2009000090A1 - Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo. - Google Patents

Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo.

Info

Publication number
CL2009000090A1
CL2009000090A1 CL2009000090A CL2009000090A CL2009000090A1 CL 2009000090 A1 CL2009000090 A1 CL 2009000090A1 CL 2009000090 A CL2009000090 A CL 2009000090A CL 2009000090 A CL2009000090 A CL 2009000090A CL 2009000090 A1 CL2009000090 A1 CL 2009000090A1
Authority
CL
Chile
Prior art keywords
antibody
trkb
binds
individual
composition
Prior art date
Application number
CL2009000090A
Other languages
English (en)
Inventor
Kenneth R Luehrsen
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of CL2009000090A1 publication Critical patent/CL2009000090A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composición que comprende el anticuerpo; método para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo.
CL2009000090A 2008-01-17 2009-01-16 Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo. CL2009000090A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2182008P 2008-01-17 2008-01-17

Publications (1)

Publication Number Publication Date
CL2009000090A1 true CL2009000090A1 (es) 2009-07-24

Family

ID=40627621

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000090A CL2009000090A1 (es) 2008-01-17 2009-01-16 Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo.

Country Status (15)

Country Link
US (1) US8642035B2 (es)
EP (1) EP2235062A1 (es)
JP (1) JP5420568B2 (es)
KR (1) KR101290503B1 (es)
CN (1) CN102015769B (es)
AR (1) AR070202A1 (es)
AU (1) AU2009205937B2 (es)
BR (1) BRPI0906877A2 (es)
CA (1) CA2712298C (es)
CL (1) CL2009000090A1 (es)
EA (1) EA028621B1 (es)
MX (1) MX2010007841A (es)
PE (1) PE20091326A1 (es)
TW (1) TW200936608A (es)
WO (1) WO2009092049A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
HUE057625T2 (hu) 2008-10-22 2022-05-28 Array Biopharma Inc TRK kináz inhibitor szubsztituált pirazolo[1,5-a]pirimidin vegyületek
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011036297A2 (de) * 2009-09-27 2011-03-31 Ruhr-Universität-Bochum Verfahren zur therapie und diagnose von morbus alzheimer
WO2011146336A1 (en) 2010-05-20 2011-11-24 Array Biopharma Inc. Macrocyclic compounds as trk kinase inhibitors
US9880160B2 (en) 2011-03-15 2018-01-30 X-Body, Inc. Antibody screening methods
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
CN102944674B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法
US10555916B2 (en) 2013-01-25 2020-02-11 Case Western Reserve University NMDAR antagonist for the treatment of pervasive development disorders
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA2916648A1 (en) * 2013-06-26 2014-12-31 Rett Syndrome Research Trust Rett syndrome and treatments therefore
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
US9869295B2 (en) 2015-05-07 2018-01-16 General Electric Company Attachment method to install components, such as tip extensions and winglets, to a wind turbine blade, as well as the wind turbine blade and component
US9869297B2 (en) 2015-05-07 2018-01-16 General Electric Company Attachment method and system to install components, such as vortex generators, to a wind turbine blade
US9869296B2 (en) 2015-05-07 2018-01-16 General Electric Company Attachment method and system to install components, such as tip extensions and winglets, to a wind turbine blade
EA201792679A1 (ru) 2015-06-01 2018-06-29 Локсо Онколоджи, Инк. Способы диагностики и лечения злокачественной опухоли
HUE053067T2 (hu) 2015-07-16 2021-06-28 Array Biopharma Inc Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
US10100805B2 (en) 2015-10-12 2018-10-16 General Electric Compant Tip extension assembly for a wind turbine rotor blade
RU2744852C2 (ru) 2015-10-26 2021-03-16 Локсо Онколоджи, Инк. Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы
US11078287B2 (en) 2015-11-17 2021-08-03 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
WO2017176751A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
MA44612A (fr) 2016-04-04 2019-02-13 Loxo Oncology Inc Méthodes de traitement de cancers pédiatriques
JP7443057B2 (ja) 2016-05-18 2024-03-05 ロクソ オンコロジー， インコーポレイテッド （Ｓ）－Ｎ－（５－（（Ｒ）－２－（２，５－ジフルオロフェニル）ピロリジン－１－イル）－ピラゾロ［１，５－ａ］ピリミジン－３－イル）－３－ヒドロキシピロリジン－１－カルボキサミドの調製
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018069927A1 (en) * 2016-10-10 2018-04-19 The National Institute for Biotechnology in the Negev Ltd. Non-cytotoxic modified cells and use thereof
TW202300515A (zh) * 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
US10443579B2 (en) 2016-11-15 2019-10-15 General Electric Company Tip extensions for wind turbine rotor blades and methods of installing same
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11098691B2 (en) 2017-02-03 2021-08-24 General Electric Company Methods for manufacturing wind turbine rotor blades and components thereof
US10830206B2 (en) 2017-02-03 2020-11-10 General Electric Company Methods for manufacturing wind turbine rotor blades and components thereof
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3066623A1 (en) * 2017-06-06 2019-12-13 University Of Massachusetts Self-regulating aav vectors for safe expression of mecp2 in rett syndrome
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
US10920745B2 (en) 2017-11-21 2021-02-16 General Electric Company Wind turbine rotor blade components and methods of manufacturing the same
US11668275B2 (en) 2017-11-21 2023-06-06 General Electric Company Methods for manufacturing an outer skin of a rotor blade
US10913216B2 (en) 2017-11-21 2021-02-09 General Electric Company Methods for manufacturing wind turbine rotor blade panels having printed grid structures
US10865769B2 (en) 2017-11-21 2020-12-15 General Electric Company Methods for manufacturing wind turbine rotor blade panels having printed grid structures
US11390013B2 (en) 2017-11-21 2022-07-19 General Electric Company Vacuum forming mold assembly and associated methods
US10821652B2 (en) 2017-11-21 2020-11-03 General Electric Company Vacuum forming mold assembly and method for creating a vacuum forming mold assembly
US11040503B2 (en) 2017-11-21 2021-06-22 General Electric Company Apparatus for manufacturing composite airfoils
US10773464B2 (en) 2017-11-21 2020-09-15 General Electric Company Method for manufacturing composite airfoils
US11248582B2 (en) 2017-11-21 2022-02-15 General Electric Company Multiple material combinations for printed reinforcement structures of rotor blades
MA51207A (fr) * 2017-11-30 2020-10-07 Regeneron Pharma Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN108265036B (zh) * 2018-01-26 2021-04-27 山东大学齐鲁医院 一种沉默t1蛋白的重组病毒及其构建方法与应用
US11035339B2 (en) 2018-03-26 2021-06-15 General Electric Company Shear web assembly interconnected with additive manufactured components
US10821696B2 (en) 2018-03-26 2020-11-03 General Electric Company Methods for manufacturing flatback airfoils for wind turbine rotor blades
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
CA3224945A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
US20220081438A1 (en) 2018-12-19 2022-03-17 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22979A1 (es) 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
JP2006512895A (ja) * 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
WO2008058127A2 (en) * 2006-11-09 2008-05-15 Irm Llc Agonist trkb antibodies and uses thereof
CA2703329A1 (en) * 2007-10-23 2009-04-30 Novartis Ag Use of trkb antibodies for the treatment of respiratory disorders

Also Published As

Publication number Publication date
AU2009205937A1 (en) 2009-07-23
AU2009205937B2 (en) 2013-02-07
EA201001139A1 (ru) 2011-04-29
KR20100103693A (ko) 2010-09-27
TW200936608A (en) 2009-09-01
EA028621B1 (ru) 2017-12-29
CA2712298A1 (en) 2009-07-23
JP5420568B2 (ja) 2014-02-19
WO2009092049A1 (en) 2009-07-23
CA2712298C (en) 2015-11-24
US8642035B2 (en) 2014-02-04
EP2235062A1 (en) 2010-10-06
MX2010007841A (es) 2010-09-28
AR070202A1 (es) 2010-03-17
CN102015769B (zh) 2014-12-10
US20110097326A1 (en) 2011-04-28
PE20091326A1 (es) 2009-09-18
KR101290503B1 (ko) 2013-07-26
JP2011510021A (ja) 2011-03-31
BRPI0906877A2 (pt) 2015-07-28
CN102015769A (zh) 2011-04-13

Similar Documents

Publication Publication Date Title
CL2009000090A1 (es) Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo.
CL2016003014A1 (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) (divisional sol. n°230-11).
AR119754A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
CL2007003236A1 (es) Anticuerpos agonistas del receptor tirosina quinasa b (trkb); composicion farmaceutica que lo comprende; y su uso para reducir los niveles de glucosa en la sangre y/o peso corporal en un individuo que lo necesite.
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
CY1114123T1 (el) Ανθρωπινα αντισωματα υψηλης συγγενειας εναντιον ανθρωπινου υποδοχεα il-4
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
AR069775A1 (es) Anticuerpos bivalentes biespecificos
CL2008003782A1 (es) Anticuerpo bivalente bioespecifico que comprende la cadena ligera y pesada de un anticuerpo que se une a un primer antigeno donde el dominio ch3 se reemplaza por ch1, y la cadena ligera y pesada de un anticuerpo que se une a un segundo antigeno, en el que el dominio ch3 esta reemplazado por cl; metodo de preparacion; y composicion.
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
CR10237A (es) Anticuerpos contra la il-22 humana y usos para los mismos
GT200500298A (es) Formulaciones de anticuerpos
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
EA201071421A1 (ru) Анти-flt3 антитела
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
CR20110035A (es) Composiciones y Métodos para Anticuerpos que se dirigen a la Proteína de Complemento C5
ES2722300T3 (es) Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
GT200600046A (es) Terapia de combinacion
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
ECSP088508A (es) Antagonistas de neuropilina